OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Engineering precision nanoparticles for drug delivery	3059
Natural products in drug discovery: advances and opportunities	1932
The COVID-19 vaccine development landscape	1179
Advances in oligonucleotide drug delivery	1000
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	935
PROTAC targeted protein degraders: the past is prologue	880
Trends in peptide drug discovery	773
Noncoding RNA therapeutics — challenges and potential solutions	721
Emerging concepts in the science of vaccine adjuvants	581
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	559
RAS-targeted therapies: is the undruggable drugged?	540
Kinase drug discovery 20 years after imatinib: progress and future directions	483
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	438
Organs-on-chips: into the next decade	435
Evolution of the COVID-19 vaccine development landscape	433
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing	424
Macrophages as tools and targets in cancer therapy	416
Strategies for delivering therapeutics across the blood–brain barrier	400
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine	374
Targeting cancer metabolism in the era of precision oncology	373
Radiopharmaceutical therapy in cancer: clinical advances and challenges	357
Anti-obesity drug discovery: advances and challenges	340
Trends in kinase drug discovery: targets, indications and inhibitor design	324
Channelling inflammation: gasdermins in physiology and disease	306
Antisense technology: an overview and prospectus	289

FDA approves 100th monoclonal antibody product	289
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	285
The clinical landscape for AAV gene therapies	270
Poly(ADP-ribose) polymerase inhibition: past, present and future	267
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	261
The quest to slow ageing through drug discovery	253
Targeting the epigenetic regulation of antitumour immunity	251
Therapeutically harnessing extracellular vesicles	248
Targeted protein degraders crowd into the clinic	237
Navigating CAR-T cells through the solid-tumour microenvironment	231
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	229
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target	218
PI3K inhibitors are finally coming of age	215
Kinase inhibition in autoimmunity and inflammation	211
Base editing: advances and therapeutic opportunities	210
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	205
Beyond immune checkpoint blockade: emerging immunological strategies	201
Advances in TRP channel drug discovery: from target validation to clinical studies	195
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	189
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	189
Image-based profiling for drug discovery: due for a machine-learning upgrade?	188
Therapeutic strategies for thrombosis: new targets and approaches	182
Protein arginine methylation: from enigmatic functions to therapeutic targeting	181
Emerging therapeutic opportunities for integrin inhibitors	181
Advances in covalent drug discovery	175
Circadian rhythm as a therapeutic target	169
Identification of neoantigens for individualized therapeutic cancer vaccines	166
Therapeutic strategies targeting FOXO transcription factors	160
RNA therapeutics on the rise	159
Advances in therapeutic peptides targeting G protein-coupled receptors	159
Pharmacological targeting of endoplasmic reticulum stress in disease	156
Function and therapeutic value of astrocytes in neurological diseases	154
Next-generation stem cells — ushering in a new era of cell-based therapies	153
Advances in targeting ‘undruggable’ transcription factors with small molecules	146
Targeting Notch in oncology: the path forward	142
Antitumour dendritic cell vaccination in a priming and boosting approach	142
Drugging p53 in cancer: one protein, many targets	141
2020 FDA drug approvals	138
Targeting RNA structures with small molecules	138
Engineering living therapeutics with synthetic biology	136
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	132
Targeting HER2-positive breast cancer: advances and future directions	129
Lipogenesis inhibitors: therapeutic opportunities and challenges	121
The PROTACtable genome	112
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	112
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	111
The emerging role of mass spectrometry-based proteomics in drug discovery	107
Therapeutic strategies for COVID-19: progress and lessons learned	107
Targeting co-stimulatory molecules in autoimmune disease	104
Impact of COVID-19 on oncology clinical trials	96

Exosome-based candidates move into the clinic	94
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	92
A tale of two antiviral targets — and the COVID-19 drugs that bind them	89
Modulating biomolecular condensates: a novel approach to drug discovery	87
Drugging the efferocytosis process: concepts and opportunities	87
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	86
Engineering the next generation of cell-based therapeutics	86
Immune targets for therapeutic development in depression: towards precision medicine	86
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	83